Autoimmunity Center of Excellence (ACE) at Stanford
斯坦福大学自身免疫卓越中心 (ACE)
基本信息
- 批准号:8461899
- 负责人:
- 金额:$ 62.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-05-01 至 2014-04-30
- 项目状态:已结题
- 来源:
- 关键词:Academic Medical CentersAddressAdultAdult-Onset Still&aposs DiseaseAffectAge of OnsetAnimalsAntibodiesAntigensAreaAutoantibodiesAutoimmune DiseasesAutoimmune ProcessAutoimmunityBasic ScienceBiological AssayBiological MarkersBiopsyBlindedBloodBlood CellsBlood CirculationBlood VesselsBlood specimenBronchoalveolar Lavage FluidCD28 geneCD3 AntigensCD4 Positive T LymphocytesCSF3 geneCell LineageCell surfaceCellsCellular biologyCharacteristicsChildChildhoodChronic Childhood ArthritisClinicalClinical ImmunologyClinical InvestigatorClinical ResearchClinical TrialsCollaborationsComplexCutaneousDataDefectDegenerative polyarthritisDermatologicDermatologyDermisDevelopmentDiffuse SclerodermaDisciplineDiseaseDisease-Modifying Second-Line DrugsDouble-Blind MethodEducationEducational MaterialsEducational process of instructingEffector CellElementsEndothelial CellsEnrollmentEragrostisEthnic groupFaceFacultyFibrosisFlareFreezingFrequenciesFundingGastroesophageal reflux diseaseGene ExpressionGoalsGranulocyte-Macrophage Colony-Stimulating FactorHandHelper-Inducer T-LymphocyteHumanIL17 geneIL2RA geneImmuneImmunohistochemistryImmunologic MonitoringImmunotherapeutic agentIn VitroInfiltrationInflammationInfusion proceduresInstructionInterferon Type IIInterferonsInterleukin 2 ReceptorInterleukin-1Interleukin-17Interleukin-2Interleukin-4Interleukin-6Interleukin-8InvestigationJointsKnowledgeLaboratoriesLaboratory ResearchLeadLeadershipLegal patentLesionLymphocyteMaintenanceMediatingMedicalMethotrexateMicroscopicModelingMonoclonal AntibodiesMononuclearMusOrganOutcomePapillaryPathogenesisPathologicPathway interactionsPatientsPeptidesPeripheral Blood Mononuclear CellPharmaceutical PreparationsPhasePhysical therapyPhysiologicalPilot ProjectsPlacebosPlasmaPlayPopulationPrevalenceProcessProductionProductivityProteinsPsoriasisPsoriatic ArthritisPublishingPulmonologyRNAReagentRegulationRegulatory T-LymphocyteReportingResearchResearch PersonnelResearch Project GrantsResearch ProposalsResourcesRheumatoid ArthritisRheumatologyRoleSafetySamplingScheduleScientistSclerodermaSerumSignal TransductionSiteSkinSkin ManifestationsStaining methodStainsSurvival RateSymptomsSynovial FluidSynovial MembraneSystemic Lupus ErythematosusSystemic SclerodermaT memory cellT-Cell ActivationT-Cell ProliferationT-LymphocyteTNF geneTechnologyTestingTherapeuticTherapeutic InterventionTissuesTranslatingTranslational ResearchTranslationsTreatment EfficacyUnited StatesUniversitiesUrineValidationVasodilator AgentsVisitWomanWorkactive methodantimicrobial peptidearthropathiesbasebody systemcomparative efficacycontrol trialcytokineefalizumabefficacy testinghigh schoolimmunoregulationimprovedinsightinterestkeratinocyteloss of functionmacrophagemedical schoolsmemory CD4 T lymphocytemennew technologynovelnovel strategiesnovel therapeuticsperipheral bloodpre-clinicalpreventprogramsresearch studyresponseskin disordersuccesssystemic autoimmune diseasetechnology developmenttherapeutic targettherapy developmenttraffickingtreatment durationtreatment strategyurinary
项目摘要
DESCRIPTION (provided by applicant): The Stanford ACE will support an integrated basic and clinical research program focused on tolerance induction and immune modulation to prevent or treat autoimmune disease. The major theme of the Stanford Autoimmunity Center of Excellence (the Center) is the study of the regulation of CD4 T cells in pathogenesis and treatment of autoimmune diseases. The Center will support and be supported by other ACE groups across the United States; and will take advantage of Stanford's documented leadership in basic and clinical research, technology development, and education in clinical immunology. Success of the Center will be supported by the interrelationships previously established at Stanford among clinician scientists from multiple departments studying autoimmune diseases in multiple organs and tissues. The Stanford ACE will be composed of outstanding basic and clinical investigators from multiple disciplines at Stanford Medical School and proposes both a basic Research Project, centered on CD4 T cell unresponsiveness, and a translational Research Project to study a new T cell lineage (termed Th17 cells) that is characterized by the ability of these lymphocytes to secrete high levels of the proinflammatory cytokine interleukin-17 (IL-17). Proposed clinical research projects encompass three different autoimmune diseases [diffuse systemic sclerosis (SSc), psoriatic arthritis and systemic juvenile idiopathic arthritis (SJIA)] that afflict adults and children, as well as organ systems including joints, skin, blood elements, and blood vessels, and will both test efficacy of therapy and develop tests to characterize the mechanisms of action of these therapeutics. The proposed Pilot and Feasibility Project proposes a two year research plan in Systemic Juvenile Idiopathic Arthritis (SJIA) patients to identify and validate urine peptide biomarkers that predict (a) response to TNF inhibition; (b) response to IL-1 inhibition; and (c) impending disease flare. In addition, this proposal will provide other ACE groups access to cutting edge reagents and technology platforms for studying human autoimmune diseases, and dissemination of Educational Materials that can be used by other ACEs to teach clinical immunology concepts to high school, undergraduate, graduate, postgraduate, and clinical fellows and faculty.
The Stanford ACE proposes to support integrated basic, pre-clinical and clinical research by proposing and then conducting basic and translational research into the mechanism of CD4 T cell unresponsiveness; two clinical trials that include novel therapies and mechanistic studies of these therapies for autoimmune diseases; and a pilot proposal that intends to develop new bi omarkers of disease.
PROJECT 1A: Clinical Component (Genovese, M)
CLINICAL COMPONENT DESCRIPTION (provided by applicant): Stanford University Medical Center (SUMC) has an extraordinary tradition of medical, translational, and basic science research. An outstanding array of resources, faculty, and facilities will be available to support the proposed ACE site at Stanford University. This proposal brings together a skilled group of translational researchers with a track record of productivity in both laboratory and clinical research focusing on human autoimmune mediated diseases. Stanford has brought together various disciplines to demonstrate both accomplishment and ability to work together with the following fields represented: Adult Rheumatology, Dermatology, Pulmonary Medicine, and Pediatric Rheumatology. The projects chosen for this submission highlight the significant collaborations that exist between Rheumatology (Adult and Pediatric), Dermatology and Pulmonary Medicine. Both clinical trials projects explore dermatologic and rheumatologic manifestations of diseases such as Psoriatic arthritis and Systemic Sclerosis. Clinical Trial Concept 1: The use of an anti- IL-17 mab in the treatment of active Psoriatic Arthritis Primary Hypothesis: The proportion of patients achieving the ACR 20 response from Baseline to Week 14 among active Psoriatic Arthritis (PSA) subjects treated with IL-17 mab is larger than the proportion achieving ACR 20 response from Baseline to Week 14 among active PSA subjects treated with placebo Objectives: The goal of this study is to determine the safety and efficacy of a monoclonal antibody to lnterleukin-17 (IL-17 mab) in the treatment of PsA with active skin and joint disease. Clinical Trial Concept 2: The use of CTLA-4lg (abatacept) in subjects with diffuse systemic sclerosis Primary hypothesis: Given several lines of evidence supporting the role of activated T cells in affected skin, we hypothesize that inhibiting T cell activation may lead to significant clinical improvement in skin manifestations in patients with diffuse systemic sclerosis (dSSc), and that changes in tissue and blood autoantibody and cytokine profiles will be associated with clinical response. Objectives: The primary goal of this study is to determine the safety and efficacy of CTLA-4lg (Abatacept) for the treatment of cutaneous manifestations of dSSc RELEVANCE (See instructions): The Stanford ACE will support an integrated basic and clinical research program focused on tolerance induction and immune modulation to prevent or treat autoimmune (Al) disease. The Stanford ACE proposes clinical research projects that encompass three different autoimmune diseases (SSc, psoriatic arthritis and SJIA), and proposes to study the MoA of therapeutics for preventing or treating different Al diseases.
描述(由申请人提供):斯坦福ACE将支持一个综合的基础和临床研究项目,重点研究耐受性诱导和免疫调节,以预防或治疗自身免疫性疾病。斯坦福自身免疫卓越中心(中心)的主要主题是研究CD4 T细胞在自身免疫性疾病发病机制和治疗中的调节作用。该中心将支持并得到美国其他ACE组织的支持;并将利用斯坦福大学在基础和临床研究、技术开发和临床免疫学教育方面的领先地位。该中心的成功将得到斯坦福大学多个部门的临床科学家之间建立的相互关系的支持,这些科学家研究多种器官和组织的自身免疫性疾病。斯坦福ACE将由来自斯坦福医学院多个学科的优秀基础和临床研究人员组成,并提出一个以CD4 T细胞无反应性为中心的基础研究项目,以及一个研究新的T细胞谱系(称为Th17细胞)的转化研究项目,其特点是这些淋巴细胞能够分泌高水平的促炎细胞因子白细胞介素-17 (IL-17)。拟议的临床研究项目包括三种不同的自身免疫性疾病[弥漫性系统性硬化症(SSc)、银屑病关节炎和系统性青少年特发性关节炎(SJIA)],这些疾病折磨着成人和儿童,以及包括关节、皮肤、血液元素和血管在内的器官系统,并将测试治疗的疗效,并开发测试来表征这些治疗的作用机制。拟议的试点和可行性项目提出了一项为期两年的系统性幼年特发性关节炎(SJIA)患者的研究计划,以确定和验证预测(a)对TNF抑制反应的尿肽生物标志物;(b)对IL-1抑制的反应;(c)即将爆发的疾病。此外,该提案将为其他ACE小组提供研究人类自身免疫性疾病的尖端试剂和技术平台,并传播可供其他ACE使用的教育材料,以向高中,本科生,研究生,研究生和临床研究员和教师教授临床免疫学概念。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Measurement of mast cell surface molecules by high-throughput immunophenotyping using transcription (HIT).
通过转录高通量免疫表型 (HIT) 测量肥大细胞表面分子。
- DOI:10.1007/978-1-4939-1568-2_24
- 发表时间:2015
- 期刊:
- 影响因子:0
- 作者:Haddon,DJames;Jarrell,JustinA;Hughes,MichaelR;Snyder,Kimberly;McNagny,KellyM;Kattah,MichaelG;Utz,PaulJ
- 通讯作者:Utz,PaulJ
Autoantigen microarrays reveal autoantibodies associated with proliferative nephritis and active disease in pediatric systemic lupus erythematosus.
- DOI:10.1186/s13075-015-0682-6
- 发表时间:2015-06-17
- 期刊:
- 影响因子:4.9
- 作者:Haddon DJ;Diep VK;Price JV;Limb C;Utz PJ;Balboni I
- 通讯作者:Balboni I
How GRAIL controls Treg function to maintain self-tolerance.
- DOI:10.3389/fimmu.2022.1046631
- 发表时间:2022
- 期刊:
- 影响因子:7.3
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHARLES GARRISON FATHMAN其他文献
CHARLES GARRISON FATHMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHARLES GARRISON FATHMAN', 18)}}的其他基金
Whole blood gene expression to identify biomarkers of disease risk, progression and response to therapy in Type 1 diabetes
全血基因表达可识别 1 型糖尿病疾病风险、进展和治疗反应的生物标志物
- 批准号:
9918349 - 财政年份:2018
- 资助金额:
$ 62.26万 - 项目类别:
Deaf1 isoforms control changes in PTA expression in the NOD PLN during T1D pathog
Deaf1亚型控制T1D病理过程中NOD PLN中PTA表达的变化
- 批准号:
8097962 - 财政年份:2010
- 资助金额:
$ 62.26万 - 项目类别:
Deaf1 isoforms control changes in PTA expression in the NOD PLN during T1D pathog
Deaf1亚型控制T1D病理过程中NOD PLN中PTA表达的变化
- 批准号:
8485528 - 财政年份:2010
- 资助金额:
$ 62.26万 - 项目类别:
Deaf1 isoforms control changes in PTA expression in the NOD PLN during T1D pathog
Deaf1亚型控制T1D病理过程中NOD PLN中PTA表达的变化
- 批准号:
8287113 - 财政年份:2010
- 资助金额:
$ 62.26万 - 项目类别:
Deaf1 isoforms control changes in PTA expression in the NOD PLN during T1D pathog
Deaf1亚型控制T1D病理过程中NOD PLN中PTA表达的变化
- 批准号:
7887644 - 财政年份:2010
- 资助金额:
$ 62.26万 - 项目类别:
Autoimmunity Center of Excellence (ACE) at Stanford
斯坦福大学自身免疫卓越中心 (ACE)
- 批准号:
7846553 - 财政年份:2009
- 资助金额:
$ 62.26万 - 项目类别:
Autoimmunity Center of Excellence (ACE) at Stanford
斯坦福大学自身免疫卓越中心 (ACE)
- 批准号:
7798610 - 财政年份:2009
- 资助金额:
$ 62.26万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 62.26万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 62.26万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 62.26万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 62.26万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 62.26万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 62.26万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 62.26万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 62.26万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 62.26万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 62.26万 - 项目类别:
Research Grant